Table 1.
Characteristics of COVID-19-related clinical trials registered with ClinicalTrials.gov from 1 December 2019 to 19 April 2020
| Trial characteristics | All trials (n=630) |
| Enrolment status, n (%) | |
| Not yet recruiting | 314 (50) |
| Recruiting | 287 (46) |
| Active, not recruiting | 13 (2) |
| Enrolment completed | 11 (2) |
| Stopped early/suspended | 5 (1) |
| Intervention, n (%)* | |
| Drug/biologic | 509 (81) |
| Behavioural/mental health | 28 (4) |
| Physiologic | 26 (4) |
| Device | 28 (4) |
| Vaccine† | 18 (3) |
| Other | 27 (4) |
| Funding source, n (%)* | |
| Industry | 143 (23) |
| NIH/US government | 11 (2) |
| Other/none | 558 (89) |
| Location* | |
| Europe | 215 (34) |
| USA | 192 (30) |
| China | 74 (12) |
| Other Asia | 56 (9) |
| Other | 89 (14) |
| Not specified | 24 (4) |
| Number of participants, median (IQR) | 150 (60–401) |
*Trials may be listed in more than one category; totals therefore add to more than 100%.
†Includes seven vaccine trials that study the effect of tuberculosis or measles vaccines on the incidence of COVID-19 infection rather than a vaccine specific to the novel coronavirus.
NIH, National Institutes of Health.